UK Medtechs Find Common Cause On Brexit In NHS Confed's Health Alliance
Executive Summary
The UK has yet to get to the sharp end when it comes to the true effects of Brexit on future policy, trade and regulation, but the medtech industry and the national health-care provider, through the NHS Confederation, are pushing for a progressive and inclusive relationship with EU stakeholders. The Brexit Health Alliance is the latest embodiment of that drive.
You may also be interested in...
Brexit Health Alliance Adds To UK-EU Debate; Medtechs Settle Into Interim Brexit Pace
The pace of Brexit-related work that impacts the UK medtech industry shows no sign of slowing over the summer. In view of unexpected – uncomfortable for some – recent opinion poll findings, there is unlikely to be a significant change in somewhat febrile UK atmosphere anytime soon. And the future UK medtech regulatory situation still needs close attention.
UK Medtech One Year Post-Brexit Vote: Still In The Land of Uncertainty
The UK's Brexit and a failed Conservative Party election strategy last month weigh heavily on the minds of local medtech businesses, looking ahead nervously at the type of trade deal the UK might finally strike with the EU. They could be waiting a while, because the When and What are still not yet apparent – never mind that the Why still rankles with many UK medtechs. That much is clear from a brand new survey of companies, which also reveals the primacy of NHS access.
UK Medtech Upscales International Plans Ahead of Brexit
As the UK prepared to leave the EU, the local medtech industry, represented by the Association of British Healthcare Industries, has been busy finding ways to make up for any potential restrictions on market access and business development. On June 21, it announced a three-year growth plan, as explained by ABHI managing director of international Paul Benton in this Medtech Insight podcast interview.